NCT06010862

A Safety and Efficacy Clinical Study of CEA-targeted CAR-T Therapy forCEA-positive Advanced/Metastatic Malignant Solid Tumors

Study Summary

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

Want to learn more about this trial?

Request More Info

Interventions

CEA CAR-T cellsBIOLOGICAL
After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
CEA CAR-T cellsBIOLOGICAL
After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally

Study Locations

FacilityCityStateCountry
The First Affiliated Hospital of Nanchang UniversityNanchangJiangxiChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026